Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2+ Metastatic Breast Cancer (MBC) 1

Interventions

pembrolizumab 45 Carboplatin 40 Cisplatin 36 Paclitaxel 29 Nivolumab 24 Pemetrexed 24 Gemcitabine 23 Dexamethasone 21 Rituximab 18 Ipilimumab 16 Cyclophosphamide 15 Capecitabine 14 Fluorouracil 14 Docetaxel 13 atezolizumab 13 Lenalidomide 12 Trastuzumab 12 durvalumab 12 trastuzumab deruxtecan 12 Cytarabine 11 daratumumab 11 130-nm albumin-bound paclitaxel 10 Bevacizumab 10 Bortezomib 10 Prednisone 10 olaparib 10 Doxorubicin 9 Crizotinib 8 Oxaliplatin 8 venetoclax 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Lapatinib × Clear all

NCT01808573 2021-06-11

NALA

Puma Biotechnology, Inc.

Phase 3 Completed

621 enrolled 21 charts 1 FDA

HER2+ Metastatic Breast Cancer (MBC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡